Foretinib | XL880 | MET/VEGFR2/KDR Inhibitor | AmBeed-信号通路专用抑制剂

首页 / 抑制剂/激动剂 / / / Foretinib

Foretinib 99%+

货号：A169062 同义名： XL880;GSK1363089 产品仅供科研

Foretinib is an ATP-competitive inhibitor of HGFR and VEGFR, mostly for Met and KDR with IC50 of 0.4 nM and 0.9 nM in cell-free assays. Foretinib is less potent against Ron, Flt-1/3/4, Kit, PDGFRα/β and Tie-2, and with little activity to FGFR1 and EGFR.

Foretinib 化学结构
CAS号：849217-64-7

Foretinib 3D分子结构
CAS号：849217-64-7

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费分装

免费溶解
下载资料

Foretinib 纯度/质量文件

货号：A169062 标准纯度：99%+ 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Mar. Drugs, 2024, 22(5): 194. Ambeed. [ A104599 ]; • Pharmaceuticals, 2024, 17(5): 570. Ambeed. [ A224421 ]; 更多 >

VEGFR 亚型比较

产品名称	VEGFR1 ↓ ↑	VEGFR2 ↓ ↑	VEGFR3 ↓ ↑	其他靶点	纯度
Motesanib Diphosphate	++++ VEGFR1, IC50: 2 nM	++++ VEGFR2, IC50: 3 nM VEGFR2/Flk1, IC50: 3 nM	+++ VEGFR3, IC50: 6 nM	PDGFR,RET	99%+
Tivozanib	++ VEGFR1, IC50: 30 nM	+++ VEGFR2, IC50: 6.5 nM	++ VEGFR3, IC50: 15 nM		99%+
Brivanib	+ VEGFR1, IC50: 380 nM	++ Flk1, IC50: 25 nM VEGFR2, IC50: 25 nM			99%+
Regorafenib	+++ VEGFR1, IC50: 13 nM	+++ VEGFR2, IC50: 4.2 nM	+ VEGFR3, IC50: 46 nM	RET	98%
Pazopanib	+++ VEGFR1, IC50: 10 nM	++ VEGFR2, IC50: 30 nM	+ VEGFR3, IC50: 47 nM	PDGFR,c-Kit,FGFR	99%
Sitravatinib	+++ VEGFR1 (FLT1), IC50: 6 nM	+++ VEGFR2 (KDR), IC50: 5 nM	++++ VEGFR3 (FLT4), IC50: 2 nM		99%+
Foretinib	+++ VEGFR1/FLT1, IC50: 6.8 nM	++++ KDR, IC50: 0.86 nM	++++ VEGFR3/FLT4, IC50: 2.8 nM	Tie-2	99%+
MGCD-265 analog	++++ VEGFR1, IC50: 3 nM	++++ VEGFR2, IC50: 3 nM	++++ VEGFR3, IC50: 4 nM	Tie-2	99%+
Lactate	+++ VEGFR1/FLT1, IC50: 10 nM	+++ VEGFR2/Flk1, IC50: 13 nM	+++ VEGFR3/FLT4, IC50: 8 nM	c-Kit,FLT3	85%
AEE788	+ FLT1, IC50: 59 nM	+ KDR, IC50: 77 nM		EGFR	98+%
Linifanib	++++ VEGFR1/FLT1, IC50: 3 nM	++++ VEGFR2/KDR, IC50: 4 nM	+ VEGFR3/FLT4, IC50: 190 nM	FLT3	99%+
Vatalanib 2HCl	+ VEGFR1/FLT1, IC50: 77 nM	++ VEGFR2/KDR, IC50: 37 nM VEGFR2/Flk1, IC50: 270 nM	+ VEGFR3/FLT4, IC50: 660 nM	c-Kit,c-Fms	99%+
Axitinib	++++ VEGFR1/FLT1, IC50: 0.1 nM	++++ VEGFR2/KDR, IC50: 0.2 nM VEGFR2/Flk1, IC50: 0.18 nM			98%
Dovitinib	+++ VEGFR1/FLT1, IC50: 10 nM	+++ VEGFR2/Flk1, IC50: 13 nM	+++ VEGFR3/FLT4, IC50: 8 nM	c-Kit,FLT3	99%+
ZM 306416	+ VEGFR1, IC50: 0.33 μM			Src	99%+
KRN-633	+ VEGFR1, IC50: 170 nM	+ VEGFR2, IC50: 160 nM	+ VEGFR3, IC50: 125 nM	BTK,c-Kit	99%+
OSI-930	+++ FLT1, IC50: 8 nM	+++ KDR, IC50: 9 nM			99%+
Lenvatinib	++ VEGFR1/FLT1, IC50: 22 nM	++++ VEGFR2/KDR, IC50: 4.0 nM	+++ VEGFR3/FLT4, IC50: 5.2 nM		98%
NVP-BAW2881	+ hVEGFR1, IC50: 820 nM	+++ mVEGF2, IC50: 165 nM hVEGFR2, IC50: 9 nM	+ hVEGFR3, IC50: 420 nM		98%
Cediranib	+++ VEGFR1/FLT1, IC50: 5 nM	++++ VEGFR2/KDR, IC50: 0.5 nM		c-Kit	99%+
Nintedanib	++ VEGFR1, IC50: 34 nM	+++ VEGFR2, IC50: 13 nM	+++ VEGFR3, IC50: 13 nM	FLT3	99+%
BMS-794833		++ VEGFR2, IC50: 15 nM			99%+
SKLB1002		++ VEGFR2, IC50: 32 nM			98%
Cabozantinib S-malate		++++ VEGFR2/KDR, IC50: 0.035 nM			99+%
Ki8751		++++ VEGFR2, IC50: 0.9 nM		c-Kit	98+%
SU 5402		++ VEGFR2, IC50: 20 nM			98%
Rivoceranib Mesylate		++++ VEGFR2, IC50: 1 nM		RET	98+%
Ponatinib		++++ VEGFR2, IC50: 1.5 nM			98%
LY2874455		+++ VEGFR2, IC50: 7 nM			99%+
ZM323881 HCl		++++ VEGFR2, IC50: <2 nM			98%
AZD2932		+++ VEGFR-2, IC50: 8 nM		c-Kit	98%
Cabozantinib		++++ VEGFR2/KDR, IC50: 0.035 nM			98%
Sorafenib		++ VEGFR2, IC50: 90 nM VEGFR2/Flk1, IC50: 90 nM			99%
CYC-116		++ VEGFR2, Ki: 44 nM		FLT3	99%+
Golvatinib		++ VEGFR2, IC50: 16 nM			99%+
Sunitinib		+ VEGFR2 , IC50: 80 nM		FLT3	98%
RAF265		++ VEGFR2, EC50: 30 nM			99%+
PD173074					99%+
BFH772		++++ VEGFR2, IC50: 3 nM			99%+
Semaxinib		+ VEGFR2/Flk1, IC50: 1.23 μM			98%
Vandetanib		++ VEGFR2, IC50: 40 nM	+ VEGFR3, IC50: 110 nM	EGFR	98%
SAR131675			++ VEGFR3, IC50: 23 nM		99%+
ENMD-2076		+ VEGFR2/KDR, IC50: 58.2 nM	++ VEGFR3/FLT4, IC50: 15.9 nM	RET,FLT3	98%
Telatinib		+++ VEGFR2, IC50: 6 nM	++++ VEGFR3, IC50: 4 nM	c-Kit	99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Foretinib 生物活性

靶点	VEGFR1 VEGFR1/FLT1, IC50:6.8 nM VEGFR1 VEGFR1/FLT1, IC50:6.8 nM VEGFR3 VEGFR3/FLT4, IC50:2.8 nM VEGFR3 VEGFR3/FLT4, IC50:2.8 nM
描述	The overexpression and activation of the Met receptor and its ligand HGF (hepatocyte growth factor) are associated with a wide variety of human malignancies. Meanwhile, it is found that VEGFRs can cooperate with Met to induce tumor invasion and vascularization. Foretinib is a multiple RTKs inhibitor with IC50 values of 0.4, 0.9/2.8 and 3nM for Met, VEGFR2/3 and Ron, less potent to Tie-2, Flt-3, PDGFRα, KIT, VEGFR1, PDGFRβ with IC50 values of 1.1nM, 3.6nM, 3.6nM, 6.7nM, 6.8nM and 9.6nM, with almost no inhibition of FGFR1 or EGFR (measured by in vitro kinase assay). Potent inhibition of p-Met by Foretinib with IC50 values of 23 and 21nM in PC-3 and B16F10 cells, as well as the suppression of p-ERK and p-VEGFR2 induced by VEGF with IC50 of 16nM in HUVECs can be observed, suggesting the cellular RTKs inhibition. Foretinib can block HGF-induced migration with IC50 value of 44nM, as well as inhibit the anchorage-independent tumor cell colony growth of B16F10 cells with IC50 of 40nM. A further study on Inhibition of endothelial tubule formation and migration by Foretinib showed that Foretinib at concentration of 5nM or higher can both inhibit VEGF-induced tubule formation and block VEGF- or HGF-stimulated migration of HMVEC-L cells. Once daily oral administration of Foretinib at dose of 30 and 100mg/kg reduced lung surface tumor burden by 50% and 58%, respectively, in mice intravenously implanted B16F10 cells. Similarly, Foretinib at dose of 30 and 100mg/kg resulted in tumor growth inhibition of 64% and 87%, respectively, in mice bearing B16F10 solid tumors^[1].
作用机制	Foretinib is an ATP-competitive inhibitor of HGFR and VEGFR.^[1]

Foretinib 细胞研究

细胞系	浓度	检测类型	检测时间	活动说明	数据源
A172	100/300/900 nM	Function Assay	1 h	inhibits the phosphorylation of MerTK	24658326
A172	100/300/900 nM	Function Assay	1 h	inhibits the activity of Axl, Tyro3	24658326
A172	100/300/900 nM	Function Assay	1 h	decreases Akt phosphorylation in a concentration dependent manner	24658326
A172	100/300/900 nM	Growth Inhibition Assay	48 h	reduces cell survival at 900 nM significantly	24658326

Foretinib 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT01068587	Lung Cancer	Phase 1 Phase 2	Completed	-	Canada, British Columbia ... 展开 >> BCCA - Vancouver Cancer Centre Vancouver, British Columbia, Canada, V5Z 4E6 Canada, Ontario Juravinski Cancer Centre at Hamilton Health Sciences Hamilton, Ontario, Canada, L8V 5C2 Ottawa Health Research Institute - General Division Ottawa, Ontario, Canada, K1H 8L6 Univ. Health Network-Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 收起 <<
NCT00725712	Neoplasms, Gastrointestinal Tr... 展开 >>act 收起 <<	Phase 2	Completed	-	United States, Alabama ... 展开 >> GSK Investigational Site Birmingham, Alabama, United States, 35294 United States, Arizona GSK Investigational Site Scottsdale, Arizona, United States, 85258 United States, California GSK Investigational Site Los Angeles, California, United States, 90024 GSK Investigational Site Stanford, California, United States, 94305 United States, District of Columbia GSK Investigational Site Washington, D.C., District of Columbia, United States, 20007 United States, Georgia GSK Investigational Site Atlanta, Georgia, United States, 30309 United States, Illinois GSK Investigational Site Chicago, Illinois, United States, 60637 United States, Massachusetts GSK Investigational Site Boston, Massachusetts, United States, 02114 United States, Michigan GSK Investigational Site Detroit, Michigan, United States, 48201 United States, Montana GSK Investigational Site Billings, Montana, United States, 59101 United States, New Mexico GSK Investigational Site Albuquerque, New Mexico, United States, 87131 United States, New York GSK Investigational Site New York, New York, United States, 10016 GSK Investigational Site New York, New York, United States, 10021 United States, North Carolina GSK Investigational Site Durham, North Carolina, United States, 27710 United States, Oregon GSK Investigational Site Portland, Oregon, United States, 97239 United States, Texas GSK Investigational Site Austin, Texas, United States, 78705 United States, Wisconsin GSK Investigational Site Madison, Wisconsin, United States, 53792 收起 <<
NCT00725712	-		Completed	-	-

Foretinib 参考文献

[1]Qian F, Engst S, et al. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res. 2009;69(20):8009-16.

Foretinib 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

1.58mL

0.32mL

0.16mL

7.90mL

1.58mL

0.79mL

15.81mL

3.16mL

1.58mL

Foretinib 技术信息

CAS号	849217-64-7
分子式	C₃₄H₃₄F₂N₄O₆
分子量	632.654

别名	XL880;GSK1363089;EXEL-2880;GSK089
运输	蓝冰

存储条件

粉末 Sealed in dry,Store in freezer, under -20°C

液体 -20°C:3-6个月-80°C:12个月

溶解度

DMSO: 80 mg/mL(126.45 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验配方

30% propylene glycol+5% Tween 80+65% water 30 mg/mL suspension

细胞研究

细胞系	浓度	检测类型	检测时间	活动说明	数据源

A172	100/300/900 nM	Function Assay	1 h	inhibits the phosphorylation of MerTK	24658326
A172	100/300/900 nM	Function Assay	1 h	inhibits the activity of Axl, Tyro3	24658326
A172	100/300/900 nM	Function Assay	1 h	decreases Akt phosphorylation in a concentration dependent manner	24658326
A172	100/300/900 nM	Growth Inhibition Assay	48 h	reduces cell survival at 900 nM significantly	24658326
A172	100/300/900 nM	Function Assay	24 h	abrogates migration and invasion of glioma cells in a dose dependent manner	24658326
Ba/F3	0.0001-10 μM	Cell Viability Assay	72 h	inhibits cell growth in a dose dependent manner	24218589
Daoy	0.5/1/2.5 μM	Function Assay	24 h	inhibits the HGF-induced cMET pathway activation	25391241
Daoy	0.5/1/2.5 μM	Function Assay	24 h	inhibits HGF-mediated migration and invasion	25391241
Daoy	1 μM	Apoptosis Assay	24 h	induces apoptosis	25391241
Daoy	0.5/1/2.5 μM	Growth Inhibition Assay	24-96 h	inhibits cell growth in a dose dependent manner	25391241
H1573		Growth Inhibition Assay		IC50=1.62 ± 0.05 μM	21252284
H1648		Growth Inhibition Assay		IC50=1.28 ±0.12 μM	21252284
H1975		Growth Inhibition Assay		IC50=1.39 ± 0.33 μM	21252284
H596		Growth Inhibition Assay		IC50=1.21 ± 0.17 μM	21252284
H69		Growth Inhibition Assay		IC50=1.18 ± 0.08 μM	21252284
HCC78	0.01-10 μM	Cell Viability Assay	72 h	inhibits cell growth in a dose dependent manner	24218589
HN5		Growth Inhibition Assay		IC50=0.65 ± 0.26 μM	21252284
HOP92		Growth Inhibition Assay		IC50=0.81 ± 0.29 μM	21252284
KATO-III	0.01-10 μM	Growth Inhibition Assay	5 d	IC50=30 nM	21655918
KATO-III	1 μM	Function Assay	24 h	inhibits phosphorylation of MET, Akt, and ERK1/2 in MKN-45	21655918
MKN-45	0.01-10 μM	Growth Inhibition Assay	5 d	IC50=8 nM	21655918
MKN-45	1 μM	Function Assay	24 h	inhibits phosphorylation of MET, Akt, and ERK1/2 in MKN-45	21655918
ONS76	0.5/1/2.5 μM	Function Assay	24 h	inhibits the HGF-induced cMET pathway activation	25391241
ONS76	0.5/1/2.5 μM	Function Assay	24 h	inhibits HGF-mediated migration and invasion	25391241
SCC15		Growth Inhibition Assay		IC50=0.63 ± 0.04 μM	21252284
SF188	100/300/900 nM	Function Assay	1 h	inhibits the phosphorylation of MerTK	24658326
SF188	100/300/900 nM	Function Assay	1 h	inhibits the activity of Axl, Tyro3	24658326
SF188	100/300/900 nM	Function Assay	1 h	decreases Akt phosphorylation in a concentration dependent manner	24658326
SF188	100/300/900 nM	Function Assay	28 h	induces PARP cleavage	24658326
SF188	100/300/900 nM	Growth Inhibition Assay	48 h	reduces cell survival at 900 nM significantly	24658326
SF188	100/300/900 nM	Function Assay	24 h	abrogates migration and invasion of glioma cells in a dose dependent manner	24658326
SK-HEP1	0.25-1.5 μM	Cell Viability Assay	24 h	inhibits cell growth in a dose dependent manner	22187171
SK-HEP2	1 μM	Function Assay	24 h	blocks HGF-induced cell motility	22187171
SK-HEP2	1 μM	Function Assay	24 h	causes G2/M phase arrest with reduction in the G0/G1 and S phases	22187171
U251	100/300/900 nM	Function Assay	1 h	inhibits the phosphorylation of MerTK	24658326
U251	100/300/900 nM	Function Assay	1 h	inhibits the activity of Axl, Tyro3	24658326
U251	100/300/900 nM	Function Assay	1 h	decreases Akt phosphorylation in a concentration dependent manner	24658326
U251	100/300/900 nM	Function Assay	28 h	induces PARP cleavage	24658326
U251	100/300/900 nM	Growth Inhibition Assay	48 h	reduces cell survival at 900 nM significantly	24658326
U251	100/300/900 nM	Function Assay	24 h	abrogates migration and invasion of glioma cells in a dose dependent manner	24658326

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT01068587	Lung Cancer	Phase 1 Phase 2	Completed	-	Canada, British Columbia ... 展开 >> BCCA - Vancouver Cancer Centre Vancouver, British Columbia, Canada, V5Z 4E6 Canada, Ontario Juravinski Cancer Centre at Hamilton Health Sciences Hamilton, Ontario, Canada, L8V 5C2 Ottawa Health Research Institute - General Division Ottawa, Ontario, Canada, K1H 8L6 Univ. Health Network-Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 收起 <<
NCT00725712	Neoplasms, Gastrointestinal Tr... 展开 >>act 收起 <<	Phase 2	Completed	-	United States, Alabama ... 展开 >> GSK Investigational Site Birmingham, Alabama, United States, 35294 United States, Arizona GSK Investigational Site Scottsdale, Arizona, United States, 85258 United States, California GSK Investigational Site Los Angeles, California, United States, 90024 GSK Investigational Site Stanford, California, United States, 94305 United States, District of Columbia GSK Investigational Site Washington, D.C., District of Columbia, United States, 20007 United States, Georgia GSK Investigational Site Atlanta, Georgia, United States, 30309 United States, Illinois GSK Investigational Site Chicago, Illinois, United States, 60637 United States, Massachusetts GSK Investigational Site Boston, Massachusetts, United States, 02114 United States, Michigan GSK Investigational Site Detroit, Michigan, United States, 48201 United States, Montana GSK Investigational Site Billings, Montana, United States, 59101 United States, New Mexico GSK Investigational Site Albuquerque, New Mexico, United States, 87131 United States, New York GSK Investigational Site New York, New York, United States, 10016 GSK Investigational Site New York, New York, United States, 10021 United States, North Carolina GSK Investigational Site Durham, North Carolina, United States, 27710 United States, Oregon GSK Investigational Site Portland, Oregon, United States, 97239 United States, Texas GSK Investigational Site Austin, Texas, United States, 78705 United States, Wisconsin GSK Investigational Site Madison, Wisconsin, United States, 53792 收起 <<
NCT00725712	-		Completed	-	-
NCT00726323	Carcinoma, Renal Cell	Phase 2	Completed	-	United States, California ... 展开 >> GSK Investigational Site Greenbrae, California, United States, 94904-2007 GSK Investigational Site San Francisco, California, United States, 94115 GSK Investigational Site Stanford, California, United States, 94305 United States, Indiana GSK Investigational Site Indianapolis, Indiana, United States, 46202 United States, Maryland GSK Investigational Site Bethesda, Maryland, United States, 20892 United States, Massachusetts GSK Investigational Site Boston, Massachusetts, United States, 02115 United States, Michigan GSK Investigational Site Detroit, Michigan, United States, 48201 United States, New Jersey GSK Investigational Site New Brunswick, New Jersey, United States, 08901 United States, Ohio GSK Investigational Site Cleveland, Ohio, United States, 44195 United States, Pennsylvania GSK Investigational Site Philadelphia, Pennsylvania, United States, 19104 United States, Tennessee GSK Investigational Site Nashville, Tennessee, United States, 37232 United States, Texas GSK Investigational Site San Antonio, Texas, United States, 78229 收起 <<
NCT00725764	Neoplasms, Head and Neck	Phase 2	Completed	-	United States, Georgia ... 展开 >> GSK Investigational Site Atlanta, Georgia, United States, 30309 United States, Illinois GSK Investigational Site Chicago, Illinois, United States, 60637 United States, Indiana GSK Investigational Site Indianapolis, Indiana, United States, 46254 United States, Minnesota GSK Investigational Site Minneapolis, Minnesota, United States, 55407-3799 United States, Missouri GSK Investigational Site Saint Louis, Missouri, United States, 63110 United States, New Hampshire GSK Investigational Site Lebanon, New Hampshire, United States, 03756 United States, South Carolina GSK Investigational Site Charleston, South Carolina, United States, 29403 United States, Tennessee GSK Investigational Site Nashville, Tennessee, United States, 37203 United States, Texas GSK Investigational Site Houston, Texas, United States, 77030 GSK Investigational Site San Antonio, Texas, United States, 78229 United States, West Virginia GSK Investigational Site Morgantown, West Virginia, United States, 28506 收起 <<
NCT00743067	Solid Tumours	Phase 1	Completed	-	-
NCT00742131	Solid Tumours	Phase 1	Completed	-	-
NCT02034097	Cancer	Phase 2	Withdrawn(GSK has decided to t... 展开 >>erminate the Product Development of foretinib and conclude our Development Agreement with Exelixis) 收起 <<	December 2016	-
NCT01147484	Recurrent Breast Cancer	Phase 2	Completed	-	Canada, Alberta ... 展开 >> Tom Baker Cancer Centre Calgary, Alberta, Canada, T2N 4N2 Canada, British Columbia BCCA - Cancer Centre for the Southern Interior Kelowna, British Columbia, Canada, V1Y 5L3 BCCA - Vancouver Cancer Centre Vancouver, British Columbia, Canada, V5Z 4E6 Canada, Nova Scotia QEII Health Sciences Centre Halifax, Nova Scotia, Canada, B3H 1V7 Canada, Ontario Juravinski Cancer Centre at Hamilton Health Sciences Hamilton, Ontario, Canada, L8V 5C2 London Regional Cancer Program London, Ontario, Canada, N6A 4L6 Ottawa Health Research Institute - General Division Ottawa, Ontario, Canada, K1H 8L6 Canada, Quebec Hopital Charles LeMoyne Greenfield Park, Quebec, Canada, J4V 2H1 Canada, Saskatchewan Allan Blair Cancer Centre Regina, Saskatchewan, Canada, S4T 7T1 收起 <<
NCT01138384	Breast Cancer	Phase 1 Phase 2	Completed	-	Canada, British Columbia ... 展开 >> BCCA - Cancer Centre for the Southern Interior Kelowna, British Columbia, Canada, V1Y 5L3 BCCA - Vancouver Cancer Centre Vancouver, British Columbia, Canada, V5Z 4E6 Canada, Ontario Cancer Centre of Southeastern Ontario at Kingston Kingston, Ontario, Canada, K7L 5P9 London Regional Cancer Program London, Ontario, Canada, N6A 4L6 Canada, Quebec McGill University - Dept. Oncology Montreal, Quebec, Canada, H2W 1S6 收起 <<
NCT00726323	-		Completed	-	-
NCT00725764	-		Completed	-	-
NCT00920192	Carcinoma, Hepatocellular	Phase 1	Completed	-	Hong Kong ... 展开 >> GSK Investigational Site Hong Kong, Hong Kong Taiwan GSK Investigational Site Tainan, Taiwan, 70428 GSK Investigational Site Taipei, Taiwan, 110 GSK Investigational Site Taipei, Taiwan, 112 Thailand GSK Investigational Site Bangkok, Thailand, 10400 GSK Investigational Site Bangkok, Thailand, 10700 GSK Investigational Site Khon Kaen, Thailand, 40002 收起 <<
NCT00742261	Solid Tumours	Phase 1	Completed	-	United States, Michigan ... 展开 >> GSK Investigational Site Detroit, Michigan, United States, 48201 United States, Texas GSK Investigational Site Houston, Texas, United States, 77030-4009 收起 <<

Foretinib 99%+

Foretinib 纯度/质量文件

全球学术期刊中引用的产品

Foretinib 生物活性

Foretinib 细胞研究

Foretinib 临床研究

Foretinib 参考文献

Foretinib 实验方案

Foretinib 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

VEGFR1	VEGFR1/FLT1, IC50:6.8 nM
VEGFR1	VEGFR1/FLT1, IC50:6.8 nM
VEGFR3	VEGFR3/FLT4, IC50:2.8 nM
VEGFR3	VEGFR3/FLT4, IC50:2.8 nM
VEGFR2	KDR, IC50:0.86 nM
VEGFR2	KDR, IC50:0.86 nM

Foretinib 99%+

Foretinib 纯度/质量文件

全球学术期刊中引用的产品

Foretinib 生物活性

Foretinib 细胞研究

Foretinib 临床研究

Foretinib 参考文献

Foretinib 实验方案

Foretinib 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z